Congressional researchers are laying out the scope and limitations of the Trump administration’s marijuana rescheduling action—explaining that while certified patients who possess medical cannabis from state-licensed dispensaries now have certain protections, the industry as a whole isn’t “immediately” considered to be in “full compliance” with federal law, particularly as it concerns recreational products.
In a report published by the Congressional Research Service (CRS) last week, analysts described the parameters of the recent final order issued by the Justice Department that moved medical marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA) and scheduled a hearing for later this summer to consider broader rescheduling.
CRS emphasized that the order “does not immediately bring the state-legal marijuana industry into compliance with federal law, but it appears to make it possible for some entities handling medical marijuana to come into compliance with the CSA.”
By placing medical cannabis in Schedule III, the federal government is acknowledging that the plant and its constituents hold currently accepted medical value that can be used for therapeutic purposes. That “opens the possibility that manufacturers, distributors, dispensers, and end users of covered marijuana products may be able to comply with the CSA,” the report
Read full article on Marijuana Moment
